Document:

Exhibit
10.15

 

FIRST
AMENDMENT TO

 

LICENSE,
FUNDING AND OPERATIONAL AGREEMENT

 

THIS
FIRST AMENDMENT (the “Amendment”) to the License, Funding and Operational Agreement between Mid-Atlantic BioTherapeutics,
Inc. (“Licensor”) and Curative Biotechnology, Inc. (“Licensee”) executed October 1, 2021 for a COVID-19 Vaccine
(the “Agreement”), is made by Licensor and Licensee,

 

WITNESSETH:

 

WHEREAS,
the Licensor and Licensee previously executed the Agreement; and

 

WHEREAS,
the Licensor and Licensee wish to amend the Agreement as set forth herein,

 

NOW,
THEREFORE, Licensor and Licensee amend the Agreement as follows:

 

	 	1.	Amendments
    to the Agreement. The following Sections of the Agreement are amended and restated as follows:

 

	 	a.	Section
    12 of the Agreement entitled “Term and Termination”, shall be deleted in its entirety and replaced with the following:

 

“Initial
Funding. Licensee shall provide Licensor $10,000,000 for the initial funding of the Project which is the subject of this Agreement
in a reasonable time frame to accomplish the initiation of the Project in a timely fashion.”

 

	 	2.	Additional
    Changes. All other provisions of this Agreement, including Sections 12.1, 12.2, 12.3 and 12.4 shall remain unchanged and in full
    force and effect except as is necessary to amend in order to effect the transactions contemplated herein, which such changes are
    hereby approved by all Parties.

 

	 	3.	Final
    Agreement. This Amendment represents the final agreement between the parties and may not be contradicted by evidence of prior,
    contemporaneous or subsequent oral agreements. There are no unwritten oral agreements between the parties.

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment this 31st day of December, 2021.

 

	LICENSOR	 	LICENSEE
	 	 	 
	Mid-Atlantic
    BioTherapeutics, Inc.	 	Curative
    Biotechnology, Inc.
	 	 	 
	 /s/ David Horn 	 	 /s/ Richard Garr 
	By:	David
    Horn, M.D.	 	Richard
    GarrExhibit
10.16

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as March 2, 2022, among Curative Biotechnology, Inc, a Florida
corporation whose principal place of business is located at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431 (the “Company”)
and the Purchaser identified on the signature pages hereto (including their successors and assigns, the “Purchaser”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of
1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and
sell to the Purchaser, and each Purchaser desires to purchase from the Company, securities of the Company as more fully described in
this Agreement.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser, severally and not jointly, agrees as set forth below.

 

ARTICLE
I

DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined
herein have the meanings given to such terms in the Notes and Warrants (as defined herein), and (b) the following terms have the meanings
set forth in this Section 1.1:

 

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affidavit
of Confession of Judgment” means the Affidavit of Confession of Judgment dated the date hereof, executed by the Company.

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 144 under the Securities Act.

 

“Business
Day” means any day except Saturday, Sunday and any day which shall be a federal legal holiday in the United States or a day
on which banking institutions in the State of New York are authorized or required by law or other government action to close.

 

“Change
of Control” means the occurrence of any of (i) an acquisition after the date hereof by an individual or legal entity or “group”
(as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) other than a group including Paul M. Michaels, Barry A. Ginsberg,
Michael J. Grace, Ronald Bordens and Richard Garr of effective control (whether through legal or beneficial ownership of capital stock
of the Company, by contract or otherwise) of in excess of 50% of the voting securities of the Company, or (ii) the Company merges into
or consolidates with any other Person, or any Person merges into or consolidates with the Company and, after giving effect to such transaction,
the stockholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power of the Company
or the successor entity of such transaction, or (iii) the Company sells or transfers all or substantially all of its assets to another
Person and the stockholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power of the
acquiring entity immediately after the transaction, (iv) a replacement at one time or within a three year period of more than one-half
of the members of the Company’s board of directors which is not approved by a majority of those individuals who are members of
the board of directors on the date hereof (or by those individuals who are serving as members of the board of directors on any date whose
nomination to the board of directors was approved by a majority of the members of the board of directors on the date hereof), or (v)
either Richard Garr, or Paul Michaels are terminated by the Company without cause (as that term will be described in their respective
employment agreements or are otherwise no longer employed by the Company on a full time basis as Chief Executive Officer or Chairman
of the Board and President, respectively, on a full time basis, (vi) the execution by the Company of an agreement to which the Company
is a party or by which it is bound, providing for any of the events set forth above in (i) through (v) above.

 

    	Page 1 of 32

    	 

    

 

“Closing”
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.

 

“Closing
Date” means the Business Day when all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchaser’ obligations to pay the Subscription Amount and (ii) the Company’s
obligations to deliver the Securities have been satisfied or waived.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $.0001 per share.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Company
Counsel” means Silvestre Law Group, P.C.

 

“Disclosure
Schedules” shall have the meaning ascribed to such term in Section 3.1 hereof.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Exempt
Issuance” means the issuance of (a) options, not to exceed 10% of the Company’s issued and outstanding Common Stock in
any one year, to purchase shares of Common Stock to employees, officers, directors or consultants of the Company, pursuant to any stock
or option plan duly adopted by the Board of Directors of the Company or a majority of the members of a committee of non-employee directors
established for such purpose, (b) shares of Common Stock issuable upon exercise, conversion or pursuant to the terms of the Securities,
or convertible securities, options or warrants issued and outstanding on the date of this Agreement, provided that such securities have
not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise, exchange or
conversion price of any such securities, (c) shares issued to unaffiliated third parties for legal, financial or other services provided
to the Company, and (d) securities issued pursuant to acquisitions or strategic transaction, provided that any such issuance shall only
be to a person which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the
Company and in which the Company receive benefits in addition to the investment of funds, but shall not include a transaction in which
the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in
securities.

 

    	Page 2 of 32

    	 

    

 

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h) hereof.

 

“IP
Security Agreement” means the Intellectual Property Security Agreement, dated as of the date hereof, by and between the Company
and the Purchaser.

 

“Liens”
means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Lock-up
Agreements” means the lock-up agreements executed by management and certain significant shareholders of the Company.

 

“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b) hereof.

 

“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(m).

 

“Notes”
means the 12.5% Senior Secured Notes due March 2, 2023 in aggregate principal amount of $1,142,857.14 issued by the Company to the Purchaser
hereunder, in substantially the same form as contained in Exhibit A hereto.

 

“OFAC”
shall mean the United States Department of the Treasury’s Office of Foreign Assets Control.

 

“OFAC
Regulations” shall mean the regulations promulgated by OFAC, as amended from time to time.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such
as a deposition), whether commenced or threatened.

 

“Qualified
Offering” means a debt (including convertible debt) or equity financing of either the Company or its Subsidiary’s securities
resulting in aggregate gross proceeds to the Company of at least $10,000,000. For purposes of clarity, to qualify as a Qualified Offering,
the gross proceeds must be raised in one (1) offering (which may have one or several closings) and the proceeds of multiple offerings
of securities with different terms will not be aggregated together.

 

    	Page 3 of 32

    	 

    

 

“Registrable
Securities” means, as of any date of determination, (a) all shares of Common Stock then issued and issuable upon conversion
in full of the Notes (assuming Event of Default) and (b) all shares of Common Stock issuable upon exercise of the Warrants (assuming
on such date the Warrants are exercised in full without regard to any exercise limitations therein), and (c) any securities issued or
then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing;
provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required
to file a registration statement pursuant to Section 4.17 (with respect thereto) for so long as (a) a Registration Statement with respect
to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities
have been disposed of by the Purchaser in accordance with an effective registration statement, (b) such Registrable Securities have been
previously sold in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions
and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered
and acceptable to the Transfer Agent and the Purchaser (assuming that such securities and any securities issuable upon exercise, or conversion
of which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company, and all Warrants are exercised
by “cashless exercise” as provided in Section 2(c) of each of the Warrants.

 

“Registration
Statement” means a registration statement that registers the resale of all shares of Common Stock which are issuable upon conversion
or exercise of the Note and/or Warrants that names the Purchaser as a “selling stockholder” therein.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to
time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Securities”
means the Note, the Warrants the and the shares of common underlying the Notes (upon an Event of Default) and Warrants.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Security
Agreement” means the Security Agreement, dated the date hereof, between the Company, the Purchaser.

 

“Security
Documents” means the Security Agreement and the IP Security Agreement and any other documents and filings required thereunder
(all UCC-1 and IP filing receipts) in order to grant the Purchaser a perfected first priority security interest on all of the current
and future assets of the Company and its Subsidiaries.

 

“Shares”
shares of common stock of the Company.

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).

 

“Subscription
Amount” means, as to the Purchaser, the aggregate amount to be paid for Notes and Warrants purchased hereunder as specified
below such Purchaser’ name on the signature page of this Agreement and next to the heading “Subscription Amount”, in
United States Dollars and in immediately available funds.

 

“Subsidiary”
means any direct or indirect subsidiary of the Company as set forth on Schedule 3.1(a).

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

    	Page 4 of 32

    	 

    

 

“Transaction
Documents” means this Agreement, the Notes, the Warrants, the Security Agreement, the IP Security Agreement, the Affidavit
of Confession of Judgment, the Lock-up Agreements, the Transfer Agent Instructions, and any other documents or agreements executed in
connection with the transactions contemplated hereunder.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:00 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets”
published by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

“Warrants”
means the Common Stock purchase warrants to purchase up to 22,857,143 shares of Common Stock and having a term of five (5) years and
an exercise price of $0.0001, in substantially the same form as Exhibit C.

 

ARTICLE
II

PURCHASE
AND SALE

 

2.1
Closing. Subject to the terms and conditions set forth herein, Purchaser agrees to purchase from the Company and the Company agrees
to sell to Purchaser the aggregate principal amount of Notes and number of Warrants, in each case set forth opposite the name of the
Purchaser on the signature page hereto, for the purchase price set forth on such page, which purchase price shall aggregate $1,000,000
which shall be payable to the Company at the Closing by wire transfer of immediately available funds. The Notes shall be issued with
an original issue discount of 12.5% (i.e., face amount is the gross proceeds/.875). In addition, upon closing, the Purchaser will receive
the Warrant as provided for in Section 2.2(a). At the Closing, Purchaser shall deliver to the Company via wire transfer immediately available
funds equal to its Subscription Amount and the Company shall deliver to each Purchaser its Note and the Warrants and the other items
set forth in Section 2.2 issuable at the Closing. Upon satisfaction of the conditions set forth in Section 2.2, the Closing shall occur
at the offices of the Company, or such other location as the parties shall mutually agree.

 

2.2
Deliveries.

 

a)
On the Closing Date, the Company shall deliver to each Purchaser the following and shall have satisfied the following conditions, as
the case may be:

 

(i)
this Agreement, duly executed by the Company;

 

    	Page 5 of 32

    	 

    

 

(ii)
a duly executed Note with a principal amount equal to the amount such set forth on the signature page hereto, registered in the name
of such Purchaser, substantially in the form of Exhibit A hereto;

 

(iii)
the Warrant, registered in the name of such Purchaser, substantially in the form of Exhibit B hereto;

 

(iv)
the Security Agreement, duly executed by the Company, substantially in the form of Exhibit C hereto;

 

(v)
the Affidavit of Confession of Judgment, substantially in the form of Exhibit D hereto, duly executed by the Company;

 

(vi)
a legal opinion of Company Counsel satisfactory in form and substance to the Purchaser, substantially in the form of Exhibit E hereto;

 

(vii)
the Lock-up Agreements, executed by management and certain significant shareholders of the Company substantially in the form of Exhibit
F hereto;

 

(viii)
Certificates of the CEO and Secretary of the Company, in the form of Exhibit G, certifying as to (a) copies of the Certificate of Incorporation
and bylaws of the Company, as amended and restated as of the date hereof, (b) all actions taken and consents made by such party and its
officers and shareholders as applicable to authorize the transactions provided by the Transaction Documents, (c) the names of the officers
of such party authorized to sign the Transaction Documents , together with a sample of the true signature of such Person, (d) all conditions
set forth in this Section 2.2 have been met by such party, and (e) no event has occurred or such party anticipates occurring that has
resulted in an Event of Default under the Notes or with the passage of time would result in an Event of Default under the Notes;

 

(ix)
Certificates of good standing for the Company in the jurisdictions of its incorporation, in the principal places in which it conducts
business and in the places where it owns real estate;

 

(xiii)
Transfer Agent Instructions, executed by the Company and the Transfer Agent, substantially in the form of Exhibit H hereto; and

 

(xiv)
the IP Security Agreement, substantially in the form of Exhibit I hereto, by and between the Company and the Purchaser.

 

b)
On the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:

 

(i)
this Agreement duly executed by the Purchaser;

 

(ii)
the Purchaser’ Subscription Amount by wire transfer to the account of the Company;

 

(iii)
the Security Agreement, duly executed by the Purchaser; and

 

(iv)
the IP Security Agreement, duly executed by the Purchaser;

 

    	Page 6 of 32

    	 

    

 

2.3
Closing Conditions.

 

a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

 

(i)
the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Purchaser contained
herein;

 

(ii)
all obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and

 

(iii)
the delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement.

 

b)
The obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:

 

(i)
the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained
herein;

 

(ii)
all obligations, covenants and agreements of the Company and its Subsidiaries required to be performed at or prior to the Closing Date
shall have been performed;

 

(iii)
the Purchaser shall be reasonably satisfied with the results of its due diligence investigation of the Company;

 

(iv)
the Purchaser shall be reasonably satisfied with the quality and amount of the collateral;

 

(v)
no statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated
by the Transaction Documents;

 

(vi)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;

 

(vii)
Since the date of execution of this Agreement, no event or series of events shall have occurred that reasonably could be expected to
have or result in a Material Adverse Effect with respect to the Company;

 

(viii)
no banking moratorium have been declared either by the United States or New York State authorities, no suspension of trading shall have
been declared on the New York Stock Exchange or the NASDAQ Stock Market, nor shall there have occurred any material outbreak or escalation
of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any
financial markets which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase
the Note and Warrants at the Closing;

 

    	Page 7 of 32

    	 

    

 

(ix)
the Company shall have no outstanding Indebtedness other than as contained on Schedule 3.1(g) or pursuant to the Note; and no other securities
of the Company outstanding after the Closing Date hereof (i) shall be in default or (ii) shall reset (or shall have exercised any rights
to convert into the Securities by virtue of a most favored nations or otherwise) as a result of the issuance of the Securities.

 

(x)
The Company has engaged Aegis Capital Corporation on a firm commitment basis to consummate a Qualified Offering of equity securities;

 

(xi)
The Company shall have public current information as defined in Rule 144; and

 

(xii)
The officers and directors of the company shall have agreed in writing to convert all of their preferred stock into common stock prior
to the Qualified Offering.

 

ARTICLE
III

REPRESENTATIONS
AND WARRANTIES

 

3.1
Representations and Warranties of the Company. Except as set forth in the Disclosure Schedule, which shall be deemed a
part hereof, the Company hereby makes the representations and warranties set forth below to the Purchaser.

 

a)
Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth in Schedule 3.1(a) hereto. The Company
owns, directly or indirectly, all of the capital stock or other equity of each Subsidiary free and clear of any Liens, other than the
Lien granted to the Purchaser, and all the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are
fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.

 

b)
Organization and Qualification. Each of the Company and the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the
requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the
Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and
is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property
owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be,
could not have or reasonably be expected to result in (i) a material adverse effect on the legality, validity or enforceability of any
Transaction Documents, (ii) a material adverse effect on the results of operations, assets, business or financial condition of the Company
and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s or its Subsidiaries’ ability
to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material
Adverse Effect”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.

 

    	Page 8 of 32

    	 

    

 

c)
Authorization; Enforcement. The Company and each of its Subsidiaries has the requisite corporate power and authority to enter
into and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its respective obligations
thereunder. The execution and delivery of each of the Transaction Documents by the Company and each of its Subsidiaries and the consummation
by it of the transactions contemplated thereby have been duly authorized by all action on the part of the Company and each of its Subsidiaries
and no further action is required by the Company and each of its Subsidiaries in connection therewith. Each Transaction Document has
been (or upon delivery will have been) duly executed by the Company and each of its Subsidiaries and, when delivered in accordance with
the terms hereof, will constitute the valid and binding obligation of the Company and such Subsidiaries enforceable against the Company
and such Subsidiaries in accordance with its terms except (i) as limited by general equitable principals and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar
as indemnification and contribution provisions may be limited by applicable law.

 

d)
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and each of its Subsidiaries
and the consummation by the Company and each of its Subsidiaries of the other transactions contemplated thereby do not and will not:
(i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company
or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse
of time or both) of, any agreement, credit facility, debt or other instrument (evidencing indebtedness of the Company or any of its Subsidiaries
or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company
or any Subsidiary is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including
federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected;
except in the case of each of clauses (ii) and (iii) subject to the Required Approvals, to the Company’s knowledge, such as could
not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.

 

e)
Filings, Consents and Approvals. Except as set forth in Schedule 3.1 (e) hereto, neither the Company, its Subsidiaries
is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with,
any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and
performance by the Company or such Subsidiaries of the Transaction Documents, other than the filing of Form D with the Commission and
such filings as are required to be made under applicable state securities laws (collectively, the “Required Approvals”).

 

f)
Issuance of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens other than restrictions
on transfer provided for in the Transaction Documents. The Common Stock issuable: (i) upon conversion of the Notes (upon an Event of
Default) and (ii) the exercise of the Warrants, when issued in accordance with the terms of the Transaction Documents, will be validly
issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company, and its Subsidiaries. The Company has reserved
from its duly authorized capital stock a number of shares of Common Stock for issuance of at least equal to the amount required to satisfy
the conversion of the Note (upon an Event of Default) and exercise of the Warrants.

 

    	Page 9 of 32

    	 

    

 

g)
Capitalization. The capitalization of the Company and its Subsidiaries is as set forth on Schedule 3.1(g). Other than as set forth
on Schedule 3.1(g), the Company and the Subsidiaries have no indebtedness for money borrowed. Except as set forth on Schedule
3.1(g), the Company has not issued any capital stock since January 1, 2022. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except
as set forth on Schedule 3.1(g), as a result of the purchase and sale of the Securities, there are no outstanding options, warrants,
script rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of common stock of the Company, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares
of common stock, of the Company or securities or rights convertible or exchangeable into shares of common stock of the Company or its
Subsidiaries. Except as set forth on Schedule 3.1(g), the issuance and sale of the Securities will not obligate the Company or
any Subsidiary to issue shares of Common Stock of the Company or any Subsidiary or other securities to any Person (other than the Purchaser)
and will not result in a right of the Company’s or any of its Subsidiaries’ securities to adjust the exercise, conversion,
exchange or reset price under such securities. All of the outstanding shares of capital stock in the Company and its Subsidiaries are
validly issued, fully paid and nonassessable, have been issued in material compliance with all federal and state securities laws, and
none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder, the Board of Directors of the Company or any of its Subsidiaries or others is
required for the issuance and sale of the Securities. There are no stockholders’ agreements, voting agreements or other similar
agreements with respect to Company’s or any of its Subsidiaries’ capital stock to which the Company or any of its Subsidiaries
is a party or, to the knowledge of the Company or such Subsidiary, between or among any of the Company’s stockholders or any stockholder
of its Subsidiaries.

 

h)
Financial Statements. Except as set forth on Schedule 3.1(h), the financial statements of the Company and its Subsidiaries,
including those financial statements for each of the years ended December 31, 2021 and 2020 and the three, six and nine months periods
ended March 30, June 30 and September 30, 2021 comply in all material respects with applicable accounting requirements and the rules
and regulations of the Commission with respect thereto. Such financial statements of the Company and its Subsidiaries have been prepared
in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated subsidiaries as of and for the dates thereof and the results of operations for the periods then ended, subject, in the
case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

i)
Material Changes. Since December 31, 2021, (i) there has been no event, occurrence or development that has had or that could reasonably
be expected to result in a Material Adverse Effect, (ii) except as set forth on Schedule 3.1(i), each of the Company and its Subsidiaries
has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary
course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s, its Subsidiaries’
financial statements pursuant to GAAP or required to be disclosed in filings made with the Commission, (iii) each of the Company and
its Subsidiaries has not altered its method of accounting, (iv) each of the Company and its Subsidiaries has not declared or made any
dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem
any shares of its capital stock and (v) each of the Company and its Subsidiaries has not issued any equity securities to any officer,
director or Affiliate, except pursuant to existing stock option plans.

 

    	Page 10 of 32

    	 

    

 

j)
Litigation. To the Company’s knowledge after due inquiry, other than as set forth in Schedule 3.1(j) hereto, there is no
action, suit, inquiry, notice of violation, proceeding or investigation pending or, threatened against or affecting the Company, any
Subsidiary, or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor to the Company’s
knowledge after due inquiry, any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge
of the Company or any Subsidiary, there is not pending or contemplated, any investigation by the Commission involving the Company or
any Subsidiary or any current or former director or officer of the Company or any Subsidiary.

 

k)
Labor Relations. No material labor dispute exists or, to the knowledge of the Company or Subsidiary, is imminent with respect
to any of the employees of the Company or any Subsidiary which could reasonably be expected to result in a Material Adverse Effect.

 

l)
Compliance, Material Contracts. To the Company’s knowledge after due inquiry, except as set forth on Schedule 3.1(l) hereto,
neither the Company nor any Subsidiary (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement,
services, marketing or processing agreement or any other agreement or instrument to which it is a party or by which it or any of its
properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator
or governmental body, or (iii) is or has been in violation of any statute, rule or regulation of any governmental authority, including
without limitation all foreign, federal, state and local laws applicable to its business except in each case as could not have a Material
Adverse Effect. Except as set forth on Schedule 3.1(l), each material contract is in full force and effect and is enforceable in accordance
with its terms, and no material defaults enforceable against the Company or any Subsidiary exist thereunder. Neither the Company nor
any Subsidiary has received notice from any party to any material contract stating that it intends to terminate or amend such contract.

 

m)
Regulatory Permits and Licenses. The Company and the Subsidiaries possess all certificates, authorizations, memberships, sponsorships
and permits issued by the appropriate federal, state, local or foreign regulatory authorities or other Person necessary to conduct their
respective businesses and are in good standing under all such certificates, authorizations, memberships, sponsorship and permits, except
where the failure to possess such permits could not have or reasonably be expected to result in a Material Adverse Effect (“Material
Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.

 

    	Page 11 of 32

    	 

    

 

n)
Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
that is material to the business of the Company and the Subsidiaries and good and marketable title in all personal property owned by
them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except Liens as
do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such
property by the Company and the Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither
delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by
them under valid, subsisting and enforceable leases of which the Company and the Subsidiaries are in compliance except where failure
to do so could not reasonably be expected to have a Material Adverse Effect.

 

o)
Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights as necessary or required for use in connection with their respective businesses and which the failure to so have could
have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). Schedule 3.1(o) sets forth all
Intellectual Property Rights necessary, to the Company’s knowledge, to conduct the Company’s business as currently conducted
or as presently proposed to be conducted. The Company owns or has the right to use under the agreements or upon the terms described on
Schedule 3.1(o), to all of the Intellectual Property Rights and has taken all actions reasonable in light of its financial position
to protect the Intellectual Property Rights. Except as set forth on Schedule 3.1(o), the Company does not require any license or other
agreement to use any of the Intellectual Property Rights, except for licenses or agreements that can be obtained in the ordinary course
of business without unreasonable effort, delay, cost, or expense. With respect to each item of the Company’s Intellectual Property
Rights that any third party owns and that the Company uses pursuant to license, sublicense, agreement or permission: (i) the license,
as it relates to the Company is legal, valid, binding, enforceable, and in full force and effect in all material respects; (ii) the Company
is not, and to the Company’s knowledge, no other party to the license, sublicense, agreement or permission is in material breach
or default, and no event has occurred which with notice or lapse of time or both would constitute a material breach or default or permit
termination, modification or acceleration thereunder; (iii) the Company has not, and to the Company’s knowledge, no other party
to the license, sublicense, agreement or permission has repudiated any material provision thereof; and (iv) the Company has not granted
any sublicense or similar right with respect to the license, sublicense, agreement or permission other than as expressly permitted by
such license, sublicense, agreement or permission. Except as set forth on Schedule 3.1(o), to the Company’s knowledge, no director,
officer, or stockholder of the Company owns any rights in any Intellectual Property Rights directly or indirectly competitive with those
owned or to be used by the Company or derived from or in connection with the conduct of the Company’s business. Except as set forth
on Schedule 3.1(o), to the Company’s knowledge it is not now necessary to use any inventions or works of authorship of its employees
made outside of their employment by the Company. Except as set forth on Schedule 3.1(o), the Company has obtained from all of the Company’s
current and former officers, employees and consultants assignments to all inventions developed or conceived during their association
with the Company and relating to its business. The Company has not granted rights to manufacture, produce, assemble, license, market,
or sell its products to any other person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and
there is no existing infringement by another Person of any of the Intellectual Property Rights of others. Neither the Company nor any
Subsidiary has received a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. The Company
and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.

 

    	Page 12 of 32

    	 

    

 

p)
Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. To
the best of the Company’s knowledge, such insurance contracts and policies are accurate and complete. Neither the Company nor any
Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.

 

q)
Transactions With Affiliates and Employees. To the Company’s knowledge, other than as set forth on Schedule 3.1(q)
hereof, none of the officers, directors or employees of the Company or any Subsidiary is presently a party to any transaction with the
Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the knowledge of the Company or any Subsidiary, any entity
in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner, in each
case in excess of $50,000 other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses
incurred on behalf of the Company or any Subsidiary and (iii) for other employee benefits, including stock option agreements under any
stock option plan of the Company or any Subsidiary.

 

r)
Certain Fees. Except as set forth on Schedule 3.1(r), no brokerage or finder’s fees or commissions are or will be
payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person
with respect to the transactions contemplated by this Agreement. The Purchaser shall have no obligation with respect to any fees or with
respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection
with the transactions contemplated by this Agreement.

 

s)
Private Placement. Assuming the accuracy of the Purchaser representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company and its Subsidiaries to the Purchaser as
contemplated hereby.

 

t)
Investment Company. The Company, its Subsidiaries is not, and is not an Affiliate of, and immediately after receipt of payment
for the Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company
Act of 1940, as amended. The Company, its Subsidiaries shall conduct its business in a manner so that it will not become subject to the
Investment Company Act.

 

u)
Registration Rights. Except as contemplated by the Transactions Documents or as set forth on Schedule 3.1(u), no Person has any
right to cause the Company to effect the registration under the Securities Act of any securities of the Company.

 

    	Page 13 of 32

    	 

    

 

v)
Application of Takeover Protections. The Company’s and its Subsidiaries’ Board of Directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the Company’s or any of the Subsidiaries’ Certificate
of Incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchaser
as a result of the Purchaser’s and the Company’s, its Subsidiaries’ fulfilling their obligations or exercising their
rights under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Securities and
the Purchaser’s ownership of the Securities.

 

w)
Disclosure. As of the Closing Date, unless another date is specified, all disclosure provided to the Purchaser regarding each
of the Company, its Subsidiaries, its business and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement,
furnished by or on behalf of the Company, its Subsidiaries with respect to the representations and warranties made herein are true and
correct with respect to such representations and warranties and do not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not
misleading. The Company and its Subsidiaries acknowledge and agree that the Purchaser makes no nor has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.

 

w)
No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Subsidiaries or Affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company or its Subsidiaries for purposes of the Securities Act or any
applicable shareholder approval provisions.

 

y)
Solvency. For purposes of the representation made in this Section 3.1(y), the term the “Company” shall include
all of its Subsidiaries. Based on the financial condition of the Company as of the Closing Date after giving effect to the receipt by
the Company and its Subsidiaries of the proceeds from the sale of the Securities hereunder and the application of the proceeds thereof,
(i) the Company’s fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the
Company’s existing debts and other liabilities (including known contingent liabilities) as they mature; (ii) the Company’s
assets do not constitute unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed
to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the
Company’s, and projected capital requirements and capital availability thereof; and (iii) the current cash flow of the Company,
together with the proceeds the Company would receive, were it to liquidate all of its assets at market value, after taking into account
all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required
to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing
and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead
it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within
one year from the Closing Date. Schedule 3.1(g) sets forth all outstanding secured and unsecured Indebtedness of the Company, its Subsidiaries
or for which any such party has commitments. For the purposes of this Agreement, “Indebtedness” shall mean (a) any
liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course
of business), (b) all guaranties, endorsements and other contingent obligations in respect of Indebtedness of others, whether or not
the same are or should be reflected in such party’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable
instruments for deposit or collection or similar transactions in the ordinary course of business; and (c) the present value of any lease
payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary
is in default with respect to any Indebtedness.

 

    	Page 14 of 32

    	 

    

 

z)
Environmental Matters. To the Company’s knowledge, the Company and each of its Subsidiaries (a) is in compliance with any
and all Environmental Laws (as herein defined), (b) has received all permits, licenses or other approvals required of it under applicable
Environmental Laws to conduct its respective businesses and (c) is in compliance with all terms and conditions of any such permit, license
or approval, in each case except to the extent such noncompliance or non-receipt would not reasonably be expected to result in a Material
Adverse Effect. The term “Environmental Laws” means all applicable federal, state, local or foreign laws relating
to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater,
land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases
of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

aa)
Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and each Subsidiary has filed all necessary federal, state and foreign income and franchise tax
returns and has paid or accrued all taxes shown as due thereon (except for those contested in good faith), and the Company have no knowledge
of a tax deficiency which has been asserted or threatened against the Company or any Subsidiary.

 

bb)
No General Solicitation. Neither the Company, nor any person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchaser and
certain other “accredited investors” within the meaning of Rule 501 under the Securities Act.

 

cc)
Foreign Corrupt Practices; Patriot Act, etc. For purposes of this representation, the term the “Company” shall include
all of its Subsidiaries. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of the
Company, has (i) directly or indirectly, used any corrupt funds for unlawful contributions, gifts, entertainment or other unlawful expenses
related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees
or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made
by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated
in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. The Company and its Subsidiaries are
in compliance, in all material respects, with (a) the Trading with the Enemy Act, as amended, and each of the foreign assets control
regulations of the United States Treasury Department (31 C.F.R., Subtitle B, Chapter V, as amended) and any other enabling legislation
or executive order relating thereto, and (b) the USA Patriot Act (Title III of Pub. L. 107-56, signed into law October 26, 2001) (the
“Act”). No part of the proceeds of the Note will be used, directly or indirectly, for any payments to any governmental official
or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity,
in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices
Act of 1977, as amended. None of the Company or any of its Subsidiaries is a Person named on a list published by OFAC or a Person with
whom dealings are prohibited under any OFAC Regulations.

 

    	Page 15 of 32

    	 

    

 

dd)
Seniority. As of the Closing Date, no Indebtedness or other claim against the Company is senior or pari-passu to the Notes in
right of payment, whether with respect to interest or upon liquidation or dissolution, or otherwise, other than indebtedness secured
by purchase money security interests (which is senior only as to underlying assets covered thereby) and capital lease obligations (which
is senior only as to the property covered thereby), in each case as set forth in Schedule 3.1 (dd) hereof.

 

ee)
No Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably anticipated
by the Company or any Subsidiary to arise, between the accountants and lawyers formerly or presently employed by the Company or any Subsidiary
and, except as set forth on Schedule 3.1(ee), the Company and each Subsidiary is current with respect to any fees owed to its accountants
and lawyers. By making this representation, each of the Company and its Subsidiaries does not, in any manner, waive the attorney/client
privilege or the confidentiality of the communications between the Company and its Subsidiaries and its lawyers. The Company’s
accountants are set forth on Schedule 3.1(ee) of the Disclosure Schedule. To the knowledge of the Company, such accountants, who have
expressed their opinion with respect to the financial statements for the year ended December 31, 2021, are a registered public accounting
firm as required by the Securities Act.

 

ff)
Acknowledgment Regarding Purchaser’s Purchase of Securities. The Company and its Subsidiaries acknowledge and agree that
the Purchaser is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated hereby. The Company and its Subsidiaries further acknowledge that the Purchaser is not acting as a financial advisor or
fiduciary of the Company and its Subsidiaries (or in any similar capacity) with respect to this Agreement and the transactions contemplated
hereby and any advice given by the Purchaser or any of its representatives or agents in connection with this Agreement and the transactions
contemplated hereby is merely incidental to the Purchaser’s purchase of the Securities. The Company and its Subsidiaries further
represent to the Purchaser that the Company’s and its Subsidiaries’ decision to enter into this Agreement has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company, and their representatives.

 

gg)
Rule 506(d) Bad Actor Disqualification Representations and Covenants.

 

(i)
No Disqualification Events. Neither the Company, nor any of its predecessors affiliates, any manager, executive officer, other
officer of the Company or such Subsidiary participating in the offering, any beneficial owner (as that term is defined in Rule 13d-3
under the Exchange Act) of 20% or more of the Company’s or such Subsidiaries’ outstanding voting equity securities, calculated
on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company
or such Subsidiary in any capacity as of the date of this Agreement and on the Closing Date (each, a “Company Covered Person”
and, together, “Company Covered Persons”) is subject to any of the “Bad Actor” disqualifications described
in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification Event”), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). The Company and its Subsidiaries has exercised reasonable care to determine (i) the identity
of each person that is a Company Covered Person; and (ii) whether any Company Covered Person is subject to a Disqualification Event.
The Company and its Subsidiaries will comply with its disclosure obligations under Rule 506(e).

 

    	Page 16 of 32

    	 

    

 

(ii)
Other Covered Persons. None of the Company and its Subsidiaries is aware of any person (other than any Company Covered Person)
that has been or will be paid (directly or indirectly) remuneration in connection with the Note that is subject to a Disqualification
Event (each an “Other Covered Person”).

 

(iii)
Reasonable Notification Procedures. With respect to each Company Covered Person, the Company and its Subsidiaries has established
procedures reasonably designed to ensure that they receive notice from each such Company Covered Person of (i) any Disqualification Event
relating to that Company Covered Person, and (ii) any event that would, with the passage of time, become a Disqualification Event relating
to that Company Covered Person; in each case occurring up to and including the Closing Date.

 

(iv)
Notice of Disqualification Events. The Company will notify the Purchaser immediately in writing upon becoming aware of (i) any
Disqualification Event relating to any Company Covered Person and (ii) any event that would, with the passage of time, become a Disqualification
Event relating to any Company Covered Person and/or Other Covered Person.

 

hh)
Acknowledgment Regarding Purchaser’s Purchase of Securities. The Company and its Subsidiaries acknowledge and agree that
each Purchaser is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the other Transaction
Documents and the transactions contemplated hereby and thereby and that the Purchaser is not (i) an officer or director of the Company
or the Subsidiaries, (ii) an Affiliate of the Company or the Subsidiaries or (iii) to the knowledge of the Company or such Subsidiaries
, a “beneficial owner” of more than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the 1934
Act. The Company and the Subsidiaries further acknowledge that the Purchaser is not acting as a financial advisor or fiduciary of the
Company or its Subsidiaries (or in any similar capacity) with respect to this Agreement or the other Transaction Documents and the transactions
contemplated hereby and thereby, and any advice given by the Company or the Subsidiaries or any of its representatives or agents in connection
with this Agreement or the other Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such
Purchaser’s purchase of the Notes and Warrants.

 

ii)
Sarbanes-Oxley; Internal Accounting Controls. Each of the Company and its Subsidiaries is in material compliance with all provisions
of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. The Company and the Subsidiaries maintain a system
of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general
or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. Each of the Company and its Subsidiaries has established disclosure
controls and procedures for the Company and its Subsidiaries to ensure it can meet its current public information obligations by making
“publicly available” the information specified in Exchange Act Rule 15c2-11(a)(5)(i) to (xiv) and (xvi).

 

    	Page 17 of 32

    	 

    

 

jj)
Variable Rate Securities. The Company has not directly and/or indirectly entered into, nor has any agreement, intention and/or
obligation to enter into any Variable Rate Transaction.

 

3.2
Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants as of the date hereof and as of
the Closing Date to the Company as follows:

 

a)
Organization; Authority. The Purchaser is an entity duly organized under the laws of the jurisdiction of its organization with
full right, corporate, limited liability company or partnership power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents and otherwise to carry out its obligations thereunder. The execution, delivery and performance
by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar
action on the part of the Purchaser. Each Transaction Document to which it is a party has been duly executed by the Purchaser, and when
delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser,
enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

b)
Purchaser Representation. The Purchaser understands that the Securities are “restricted securities” and have not been
registered under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account
and not with a view to or for distributing or reselling such Securities or any part thereof, has no present intention of distributing
any of such Securities in violation of the Securities Act or any applicable securities laws and has no arrangement or understanding with
any other persons regarding the distribution of such Securities (this representation and warranty not limiting the Purchaser’s
right to sell the Securities pursuant to a registration statement or otherwise in compliance with applicable federal and state securities
laws). Nothing contained herein shall be deemed a representation or warranty by such Purchaser to hold Securities for any period of time.

 

c)
Purchaser Status. At the time such Purchaser was offered the Securities, it was, and at the date hereof it is, and on each date
on which it converts any of the Notes into shares of Common Stock it will be either: (i) an “accredited investor” as defined
in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional buyer” as
defined in Rule 144A(a) under the Securities Act.

 

d)
Experience of the Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of
an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

e)
General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or any other general solicitation or general advertisement.

 

    	Page 18 of 32

    	 

    

 

f)
Own Account. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and
not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable
state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable
state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty
not limiting such Purchaser’s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.

 

g)
Access to Information. Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all
exhibits and schedules thereto) and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to
receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits
and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations,
business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain
such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make
an informed investment decision with respect to the investment. No Person or Affiliate has made or makes any representation as to the
quality of the Securities.

 

h)
Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser’s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser’s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition
of, any actions with respect to the borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities
of the Company in order for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar transactions
in the future.

 

The
Company and its Subsidiaries acknowledge and agree that the Purchaser does not make or have not made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in this Section 3.2.

 

    	Page 19 of 32

    	 

    

 

ARTICLE
IV

OTHER
AGREEMENTS OF THE PARTIES

 

4.1
Transfer Restrictions.

 

a)
The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities
other than pursuant to an effective registration statement or Rule 144, to the Company or any Subsidiary or to an affiliate of a Purchaser
or in connection with a pledge as contemplated in Section 4.1(b), the Company may, at its expense, require the transferor thereof to
provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance
of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such
transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by
the terms of this Agreement and shall have the rights of a Purchaser under this Agreement.

 

b)
The Purchaser agrees to the imprinting, so long as is required by this Section 4.1(b), of a legend on any of the Securities in the following
form:

 

NEITHER
THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [EXERCISABLE] [CONVERTIBLE] HAVE BEEN REGISTERED WITH THE SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS THESE SECURITIES AND THE SECURITIES ISSUABLE
UPON [EXERCISE] [CONVERSION] OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY
SUCH SECURITIES.

 

c)
Certificates evidencing the Common Shares underlying the Note and the Warrant shall not contain any legend (including the legend set
forth in Section 4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities
Act, or (ii) following any sale of such Common Shares pursuant to Rule 144 , or (iii) if such Common Shares are eligible for sale under
Rule 144, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations
and pronouncements issued by the staff of the Commission). The Company shall, at its expense, cause its counsel to issue a legal opinion
to the Company’s transfer agent promptly after the Effective Date if required by the Company’s transfer agent to effect the
removal of the legend hereunder. If all or any portion of a Note is converted or Warrant is exercised at a time when there is an effective
registration statement to cover the resale of the common shares, or if such common shares may be sold under Rule 144or if such legend
is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations thereof and pronouncements
issued by the staff of the Commission) then such common shares shall be issued free of all legends. The Company agrees that following
the effective date of any registration statement providing for the resale of the Securities or at such time as such legend is no longer
required under this Section 4.1(c), it will, no later than two Business Days following the delivery by a Purchaser to the Company or
the Company’s transfer agent of a certificate representing common shares issued with a restrictive legend (such second Business
Day, the “Legend Removal Date”), deliver or cause to be delivered to such Purchaser a certificate representing such
shares that is free from all restrictive and other legends. Neither the Company may make any notation on its records or give instructions
to any transfer agent of the Company that enlarge the restrictions on transfer set forth in this Section. Certificates for common shares
subject to the legend removal hereunder shall be transmitted by the transfer agent of the Company to the Purchaser by crediting the account
of the Purchaser’ prime broker with the DTC.

 

    	Page 20 of 32

    	 

    

 

d)
In addition to the Purchaser’s other available remedies, the Company shall pay to Purchaser, in cash, as partial liquidated damages
and not as a penalty, $1000 per Trading Day for each Trading Day after the Legend Removal Date until such certificate is delivered without
a legend. Nothing herein shall limit each Purchaser’ right to pursue actual damages for the Company’s failure to deliver
certificates representing any Securities as required by the Transaction Documents, and each Purchaser shall have the right to pursue
all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.

 

e)
The Purchaser agrees that the removal of the restrictive legend from certificates representing Securities as set forth in this Section
4.1 is predicated upon the Company’s reliance that such Purchaser will sell any Securities pursuant to either the registration
requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom.

 

4.2
Acknowledgment of Dilution. The Company and its Subsidiaries acknowledge that the issuance of the Securities may result in dilution
of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions. The Company and its Subsidiaries
further acknowledge that its obligations under the Transaction Documents, including without limitation its obligation to issue the Common
Shares underlying the Notes (upon Event of Default) pursuant to the Transaction Documents, are unconditional and absolute and not subject
to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company or
its Subsidiaries may have against any Purchaser and regardless of the dilutive effect that such issuance may have on the ownership of
the other stockholders of the Company and its Subsidiaries.

 

4.3
Furnishing of Information Rule 144 Availability. 

 

a)
As long as any Purchaser owns Securities, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare
and furnish to such Purchaser and make publicly available in accordance with Rule 144(c) such information as is required for such Purchaser
to sell the Securities under Rule 144. The Company further covenants that it will take such further action as any holder of Securities
may reasonably request, all to the extent required from time to time to enable such Person to sell such Securities without registration
under the Securities Act within the limitation of the exemptions provided by Rule 144.

 

b)
At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the
Securities may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction
or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement
under Rule 144(c) or (ii) has ever been an issuer described in Rule 144 (i)(1)(i) or becomes an issuer in the future, and Company shall
fail to take such action as is reasonably requested by the Purchaser to enable the Purchasers to sell any of the shares received in connection
with the Notes or Warrants pursuant to Rule 144 under the Securities Act (including, without limitation, delivering all such legal opinions,
consents, certificates, resolutions and instructions to the Company’s transfer agent as may be reasonably requested from time to
time by the Purchaser and otherwise fully cooperate with Purchasers and each Purchaser’s broker to effect such sale of the shares
of common stock received in connection with the Notes or Warrants pursuant to Rule 144 under the Securities Act) (a “Process Failure”)
satisfy any then, in addition to such Purchaser’s other available remedies, the Company shall pay to a Purchaser, in cash, as partial
liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an amount
in cash equal to two percent (2.0%) of the aggregate principal amount of such Purchaser’s Securities on the day of a Public Information
Failure or Process Failure, as applicable, and on every thirtieth (30th) day (pro rated for periods totaling less than thirty days) thereafter
until (a) in the case of a Process Failure, the date such Process Failure is cured, or (b) in the case of a Public Information Failure,
the date such Public Information Failure is cured. Notwithstanding anything to the contrary provided herein, liquidated damages for each
Process Failure or Public Information Failure shall not commence to accrue for a period of 5 days from the date of any such Process Failure
and/or Public Information. The payments to which a Purchaser shall be entitled pursuant to this Section 4.3(b) are referred to herein
as “ Rule 144 Failure Payments.” Rule 144 Failure Payments shall be paid on the earlier of (i) the last day of the calendar
month during which such Rule 144 Failure Payments are incurred and (ii) the third (3rd) Business Day after the event or failure giving
rise to the Rule 144 Failure Payments is cured. In the event the Company fails to make Rule 144 Failure Payments in a timely manner,
such Rule 144 Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing
herein shall limit such Purchaser’s right to pursue actual damages for the Process Failure or Public Information Failure, and such
Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief.

 

    	Page 21 of 32

    	 

    

 

4.4
Integration. The Company shall not, and shall use its best efforts to ensure that no Affiliate of the Company shall, sell, offer
for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that
would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act
of the sale of the Securities to the Purchaser or that would be integrated with the offer or sale of the Securities for purposes of the
rules and regulations of any Trading Market.

 

4.5
Securities Laws Disclosure; Publicity. The Company shall by 9:00 a.m. (New York City time) on the Trading Day immediately following
the date hereof file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the SEC. From and after
the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public
information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors,
employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance
of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and
the Purchaser shall consult with each other in issuing any press releases with respect to the transactions contemplated hereby. Notwithstanding
the foregoing, the Company shall not publicly disclose the name of the Purchaser, or include the name of the Purchaser in any filing
with the Commission or any regulatory agency or Trading Market, without the prior written consent of the Purchaser, except (i) as required
by federal or state securities law and (ii) to the extent such disclosure is required by law or Trading Market regulations, in which
case the Company shall provide such Purchaser with notice of such disclosure permitted under subclause (i) or (ii).

 

4.6
Shareholder Rights Plan. No claim will be made or enforced by the Company or its Subsidiaries or, to the knowledge of any such
party, any other Person that any Purchaser is an “Acquiring Person” under any shareholder rights plan or similar plan or
arrangement in effect or hereafter adopted by the Company or its Subsidiaries, or that any Purchaser could be deemed to trigger the provisions
of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between
the Company any of its Subsidiaries and any Purchaser. The Company and its Subsidiaries shall conduct its business in a manner so that
it will not become subject to the Investment Company Act.

 

4.7
Use of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder to satisfy the obligations on
Schedule 4.7 hereof and to pay fees and expenses (in each case satisfactory to the Investor) incurred in connection herewith. The Company
may not use funds at any time to repay indebtedness, lend money, give credit or make advances to any officers, directors, employees,
affiliates or debtholders of the Company or its Subsidiaries.

 

4.8
Reimbursement. Except to the extent finally judicially determined to have been caused by Purchaser’s gross negligence or
willful misconduct, if Purchaser becomes involved in any capacity in any Proceeding by or against any Person who is a stockholder of
the Company or its Subsidiaries (except as a result of sales, pledges, margin sales and similar transactions by the Purchaser to or with
any current stockholder), solely as a result of such Purchaser’ acquisition of the Securities under this Agreement, the Company
and its Subsidiaries will reimburse such Purchaser for its reasonable legal and other expenses (including the cost of any investigation
preparation and travel in connection therewith) incurred in connection therewith, as such expenses are incurred. The reimbursement obligations
of the Company and its Subsidiaries under this paragraph shall be in addition to any liability which the Company or such Subsidiaries
may otherwise have, shall extend upon the same terms and conditions to any Affiliates of the Purchaser who are actually named in such
action, proceeding or investigation, and partners, directors, agents, employees and controlling persons (if any), as the case may be,
of such Purchaser and any such Affiliate, and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal
representatives of the Company, its Subsidiaries, the Purchaser and any such Affiliate and any such Person. The Company and its Subsidiaries
also agree that neither the Purchasers nor any such Affiliates, partners, directors, agents, employees or controlling persons shall have
any liability to the Company, its Subsidiaries, or any Person asserting claims on behalf of or in right of the Company, its Subsidiaries,
solely as a result of acquiring the Securities under this Agreement.

 

    	Page 22 of 32

    	 

    

 

4.9
Indemnification of Purchasers. Subject to the provisions of this Section 4.9, the Company and its Subsidiaries will indemnify
and hold the Purchaser and its directors, officers, shareholders, partners, employees and agents (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such
Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees of such Person (and any other Persons with a functionally equivalent role of a Person holding
such titles notwithstanding a lack of such title or any other title) (each, a “Purchaser Party”) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys’ fees and costs of investigation that any Purchaser Party may suffer or incur
as a result of, arising from, or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by
the Company and its Subsidiaries in this Agreement or in the other Transaction Documents or (b) any action instituted against a Purchaser,
or any of them or their respective Affiliates, by any stockholder of the Company or its Subsidiaries or who is not an Affiliate of such
Purchaser, with respect to any of the transactions contemplated by the Transaction Documents (in each case unless such action is based
upon a breach of such Purchaser’ representation, warranties or covenants under the Transaction Documents or any agreements or understandings
any Purchaser may have with any such stockholder or any violations by such Purchaser of state or federal securities laws or any conduct
by such Purchaser which constitutes fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser
Party in respect of which indemnity may be sought pursuant to this Agreement, the Purchaser Party shall promptly notify the Company in
writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing. Any Purchaser Party shall
have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of the Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized
by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel
or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material conflict on any material issue between
the position of the Company and the position of the Purchaser Party. The Company will not be liable to any Purchaser Party under this
Agreement (i) for any settlement by a Purchaser Party effected without the Company’s prior written consent, which shall not be
unreasonably withheld or delayed; or (ii) to the extent, but only to the extent that a loss, claim, damage or liability is attributable
to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by the Purchaser in this
Agreement or in the other Transaction Documents.

 

4.10
Reservation and Listing of Securities. At all times and as long as any of the Purchaser owns any Securities, the Company shall
take all action necessary (and/or reasonably requested by the Purchaser) to at all times have authorized, and reserved out of its authorized
but unissued shares of Common Stock for the purpose of issuance to the Purchaser upon conversions of the Note (upon an Event of Default)
and upon exercise or in respect of the Warrants by the Purchaser, no less than the sum of : (i) 150% of the maximum number of shares
of Common Stock issuable upon exercise of the Warrants and (ii) 5 times the number of shares of Common Stock issuable upon conversion
of the Note (including interest and original issue discount, and without taking into account any limitations on the issuance thereof)
(upon an Event of Default) (collectively the “Required Reserved Amount”). If at any time the number of shares of Common Stock
authorized and reserved for issuance is not sufficient to meet the Required Reserved Amount, the Company will promptly take all corporate
action necessary to authorize and reserve a sufficient number of shares, including, without limitation, calling a special meeting of
stockholders to authorize additional shares to meet the Company’s obligations under this Agreement and the Transaction Documents,
in the case of an insufficient number of authorized shares, obtain stockholder approval of an increase in such authorized number of shares,
and voting the management shares of the Company in favor of an increase in the authorized shares of the Company to ensure that the number
of authorized shares is sufficient to meet the Required Reserved Amount. The Company shall initially reserve the Required Reserve Amount
on its own books and records (the “Reserve”) for the issuance of shares underlying the Notes (upon an Event of Default) and
Warrants and any other shares of Common Stock required to be issued by the Company to the Purchaser pursuant to the Transaction Documents,
which initial reservation shall be authorized by the unanimous written consent of the Company’s Board of Directors delivered at
Closing. From and after the date of this Agreement through and including the date all of the Company’s and each of its Subsidiaries’
Indebtedness and all other obligations owed to the Purchasers pursuant to this Agreement and the other Transaction Documents, including,
but not limited to, the Note is paid and performed in full and the Warrant is exercised in full, confirmation of which must be obtained
by in writing from the Purchaser, the Company shall issue or cause its Transfer Agent to issue the shares received on conversion or exercise
or in respect of interest and all other shares of Common Stock required to be issued to such Purchaser or its broker from the Reserve.
The Company agrees to increase the amount of shares of Common Stock in the Reserve upon receipt of written notice, which may be in email
form, by such Purchaser (and/or its assigns) in order to ensure that the Reserve contains the Required Reserve Amount and/or at any time
the number of shares in the Reserve is less than the Required Reserve Amount Notwithstanding to the contrary provided herein or elsewhere,
if at any time the number of shares of Common Stock in the Reserve, is less than the Required Reserved Amount, such Purchaser may send
written notice to the Company’s then Transfer Agent to increase out of the Borrower’s authorized but unissued shares of Common
Stock in such number of additional shares of Common Stock so the Reserve consists of at least the Required Reserve Amount. The Company
agrees that the Common Stock in the Reserve shall never be decreased below the Required Reserve Amount or used for any other purposes
other than for issue to the holder thereof upon each conversion by such Purchaser of the Notes and each exercise by such Purchaser of
the Warrants into shares of common stock. As a condition to Closing, all actions required by the Company in this Section shall be approved
by the unanimous written consent of the Company’s Board of Directors which shall be delivered to the Purchasers at Closing.

 

    	Page 23 of 32

    	 

    

 

4.11
Subsequent Equity Sales. In addition to the limitations set forth herein, from the date hereof until the later of (i) the twelve
(12) month anniversary of the Closing Date and (ii) the date there are no Notes outstanding, the Company shall be prohibited from effecting
or entering into an agreement to effect any Subsequent Financing involving a “Variable Rate Transaction”. The term
“Variable Rate Transaction” shall mean a transaction in which the Company issues or sells (i) any debt, equity securities
or Common Stock Equivalents either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with
the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities,
or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business
of the Company or the market for the Common Stock or (ii) enters into any agreements, including but not limited to an equity line of
credit, whereby the Company may sell securities at a future determined price tied to the market price of the Common Stock or (iii) the
Company issues or sells any securities, for cash, in a capital raising transaction or series of related capital raising transactions
which grants to an investor the right to receive additional shares based upon future transactions of the Company on terms more favorable
than those granted to such investor in such offering. Any Purchaser shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right to collect damages. Notwithstanding the foregoing, this
Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.

 

4.12
Equal Treatment of Purchasers. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification
of any provision of any of the Transaction Documents unless the same consideration is also offered to all of the parties to the Transaction
Documents. For clarification purposes, this provision constitutes a separate right granted to Purchaser by the Company and negotiated
separately by Purchaser.

 

4.13
Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation
D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably
determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under
applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly
upon request of any Purchaser.

 

4.14
Most Favored Nations. Until such time as the Company has consummated a Qualified Offering which results in the Company’s
Common Stock becoming listed on a national exchange (NASDAQ or NYSE American), if the Company engages in any future capital raising transactions
pursuant to which it sells debt or equity securities for cash, with a third-party investor, the Company will provide the Holder with
written notice (the “MFN Notice”) thereof promptly but in no event less than 10 days prior to closing any such transactions.
Included with the MFN Notice shall be a copy of all documentation relating to such financing transaction and shall include, upon written
request of the Holder, any additional information related to such subsequent investment as may be reasonably requested by the Holder.
In the event the Holder determines that any of the terms of the subsequent investment are preferable in any respect to any the terms
of the Securities of the Company issued to the Holder pursuant to the terms of the Purchase Agreement (eg. conversion price, exercise
price, warrant coverage, bonus shares, etc.), the Holder shall have ten (10) days after receipt of the MFN Notice to notify the Company
in writing thereof. Promptly after receipt of such written notice from the Holder, the Company agrees to amend and restate any Securities
then held by Purchaser, and, as necessary, adjust the number of shares or exercise price or conversion price or warrant coverage, to
include the preferable term contained in the instruments evidencing the subsequent investment and any shares or warrants issued in connection
therewith. For purposes of clarity, such adjustments will only be made with regard to Securities still owned by Purchaser. If Purchaser
previously exercised all of its Warrants, Purchaser will not be entitled to any adjustment to warrant coverage or exercise.

 

    	Page 24 of 32

    	 

    

 

4.15.
Right of Participation.

 

a)
At any time prior to the 18 months anniversary of the Closing Date, upon any issuance by the Company or any of its Subsidiaries of debt,
equity or Common Stock Equivalents for cash consideration, indebtedness or a combination thereof (a “Subsequent Financing”),
the Purchaser shall have the right to participate in up to Purchaser’s initial investment amount in the Note, but not more than
15% of the Subsequent Financing (the “Participation Maximum”) on the same terms, conditions and price provided for in the
Subsequent Financing. At least five (5) Business Days prior to the closing of the Subsequent Financing, the Company shall deliver to
each Purchaser a written notice of its intention to effect a Subsequent Financing (“Pre-Notice”), which Pre-Notice shall
ask the Purchaser if it wants to review the details of such financing (such additional notice, a “Subsequent Financing Notice”).
Upon the request of a Purchaser, and only upon a request by such Purchaser, for a Subsequent Financing Notice, the Company shall promptly,
but no later than one (1) Business Day after such request, deliver a Subsequent Financing Notice to such Purchaser. The Subsequent Financing
Notice shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised
thereunder and the Person or Persons through or with whom such Subsequent Financing is proposed to be effected and shall include a term
sheet or similar document relating thereto as an attachment.

 

b)
If a Purchaser desires to participate in such Subsequent Financing it must provide written notice to the Company by not later than 5:30
p.m. (New York City time) on the fifth (5th) Business Day after the Purchaser has received the Pre-Notice that such Purchaser
is willing to participate in the Subsequent Financing, the amount of such Purchaser’s participation, and representing and warranting
that such Purchaser has such funds ready, willing, and available for investment on the from the Purchaser as of such fifth (5th)
Business Day, the Purchaser shall be deemed to have notified the Company that it does not elect to participate.

 

c)
If by 5:30 p.m. (New York City time) on the fifth (5th) Business Day after a Purchaser has received the Pre-Notice, notifications
by the Purchasers of their willingness to participate in the Subsequent Financing (or to cause their designees to participate) is, in
the aggregate, less than the total amount of the Subsequent Financing, then the Company may effect the remaining portion of such Subsequent
Financing on the terms and with the Persons set forth in the Subsequent Financing Notice.

 

d)
If by 5:30 p.m. (New York City time) on the fifth (5th) Business Day after the Purchaser has received the Pre-Notice, the
Company receives responses to a Subsequent Financing Notice from Purchaser seeking to purchase more than the aggregate amount of the
Participation Maximum, the Purchaser shall have the right to purchase its pro rata portion of the Participation Maximum.

 

e)
The Company must provide the Purchaser with a second Subsequent Financing Notice, and the Purchasers will again have the right of participation
set forth above in this Section 4.15, if the Subsequent Financing subject to the initial Subsequent Financing Notice is not consummated
for any reason on the terms set forth in such Subsequent Financing Notice within thirty (30) Business Days after the date of the initial
Subsequent Financing Notice.

 

    	Page 25 of 32

    	 

    

 

f)
The Company and the Purchasers agree that if any Purchaser elects to participate in the Subsequent Financing, the transaction documents
related to the Subsequent Financing shall not include any term or provision whereby such Purchaser shall be required to agree to any
restrictions on trading as to any of the Securities purchased hereunder or be required to consent to any amendment to or termination
of, or grant any waiver, release or the like under or in terms set forth in the Subsequent Financing Notice.

 

g)
Notwithstanding the foregoing, this Section 4.15 shall not apply in respect of an Exempt Issuance.

 

4.16
Directors’ and Officers’ Insurance. For so long as any of the Note is outstanding, the Company shall retain directors’
and officers’ insurance in amounts and on terms customary for companies in the same industry of similar size as the Company.

 

4.17
Piggyback Registration Rights. At any time while there are any Registrable Securities outstanding:

 

a)
if the Company determines to register any of its securities, either for its own account or the account of a security holder or holders,
other than (i) a registration statement relating solely to employee benefit plans on Form S-8 (or any successor form) or (ii) a registration
statement relating solely to a Commission Rule 145 transaction on Form S-4 (or any successor form), the Company will:

 

(i)
promptly give to the Purchaser written notice thereof, and

 

(ii)
include in such registration statement (and any related qualification under blue sky laws or other compliance), and in any underwriting
involved therein, all the Registrable Securities specified in a written request or requests, made within 5 Business Days after delivery
of such written notice from the Company.

 

b)
If the registration statement of which the Company gives notice is for a registered public offering involving an underwriting, the Company
shall so advise the Purchaser as a part of the written notice described above.

 

(i)
If the managing underwriter determines in good faith that marketing factors (including pricing) require a limitation of the number of
shares to be underwritten, the underwriter may exclude some or all of the Registrable Securities from such registration and underwriting.
The Company shall so advise Purchaser, and the number of Registrable Securities to be included in such registration shall be allocated
as follows: first, for the account of the Company, all shares proposed to be sold by the Company; second, for the account of the Purchaser
and any other unaffiliated investor that has been granted registration rights with respect to shares on the terms and conditions of any
agreement pertaining to such registration rights prior to the Closing Date, pro-rata; and third, any affiliated investor of that has
been granted registration rights with respect to shares on the terms and conditions of any agreement pertaining to such registration
rights on or after the Closing Date.

 

(ii)
If the Purchaser disapproves of the terms of any such underwriting, the Purchaser may elect to withdraw by written notice to the Company
and the managing underwriter. Any shares excluded or withdrawn from such underwriting shall be withdrawn from such registration statement.

 

(iii)
The Company shall have the right to terminate or withdraw any registration initiated by it prior to the effectiveness of such registration,
whether or not the Investor has elected to include any or all of the Shares in such registration.

 

c)
All Expenses incurred in connection with any registration, filing, qualification, legal and other third party retained by the Company,
or compliance pursuant to this Section 4.17 shall be borne by the Company.

 

    	Page 26 of 32

    	 

    

 

ARTICLE
V

MISCELLANEOUS

 

5.1
Termination. This Agreement may be terminated by the Purchaser, as to such Purchaser’s obligation hereunder by written notice
to the other parties, if the Closing has not been consummated on or before March 31, 2022; provided that no such termination will affect
the right of any party to sue for any breach by the other party (or parties).

 

5.2
Fees. At the Closing, the Company has agreed to reimburse Purchaser (i) $25,000 (less any amounts previously received; such balance
may be treated as proceeds advanced and added to the face of the Note) for legal expenses incurred in connection with the transaction,
and (ii) all other costs and expenses incurred in connection with the due diligence and documentation of the transaction by the Purchaser
(e.g., background checks (to the extent not provided to Purchaser), lien searches, UCC and IP filings (including legal expenses of third
parties), etc. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the issuance
of any Securities.

 

5.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with
respect to such matters, which the parties acknowledge have been incorporated into such documents, exhibits and schedules.

 

5.4
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via email or facsimile at the facsimile number set forth on the signature pages attached hereto prior to 5:30 p.m. (New York City time)
on a Business Day, (b) the next Business Day after the date of transmission, if such notice or communication is delivered via email or
facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Business Day or later than
5:30 p.m. (New York City time) on any Business Day, (c) the second Business Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth on the signature pages attached hereto.

 

5.5
Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case
of amendments, by the Company, and the Purchaser or, in the case of a waiver, by the party against whom enforcement of any such waiver
is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a
continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

5.6
Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the
parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

5.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder. Any Purchaser may assign any or
all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided such transferee
agrees in writing to be bound, with respect to the transferred Securities, by the provisions hereof that apply to such “Purchaser.”

 

    	Page 27 of 32

    	 

    

 

5.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.9.

 

5.9
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and
federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by
law. The parties hereby waive all rights to a trial by jury. If the Purchaser shall commence an action or proceeding to enforce any provisions
of the Transaction Documents, then it shall be reimbursed by the Company for its reasonable attorneys’ fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

5.10
Survival. The representations and warranties contained herein shall survive for a period of 6 months following the Closing, the
delivery of the Note and Warrants and the conversion or payment of the Notes.

 

5.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party,
it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page or data
file were an original thereof.

 

5.12
Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.

 

5.13
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) the Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
the Company and its Subsidiaries does not timely perform their related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company , any relevant notice, demand or
election in whole or in part without prejudice to its future actions and rights.

 

    	Page 28 of 32

    	 

    

 

5.14
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company and its Subsidiaries shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate
or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement
Securities.

 

5.15
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchaser and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing
sentence and hereby agrees to waive in any action for specific performance of any such obligation the defense that a remedy at law would
be adequate.

 

5.16
Payment Set Aside. To the extent that the Company or its Subsidiaries makes a payment or payments to any Purchaser pursuant to
any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of
such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, such Subsidiary, a trustee,
receiver or any other person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable
cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall
be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

5.17
Usury. To the extent it may lawfully do so, the Company and its Subsidiaries hereby agrees not to insist upon or plead or in any
manner whatsoever claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever
enacted, now or at any time hereafter in force, in connection with any claim, action or proceeding that may be brought by any Purchaser
in order to enforce any right or remedy under any Transaction Document. Notwithstanding any provision to the contrary contained in any
Transaction Document, it is expressly agreed and provided that the total liability of the Company and its Subsidiaries under the Transaction
Documents for payments in the nature of interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum
Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default interest, or both of them, when
aggregated with any other sums in the nature of interest that the Company may be obligated to pay under the Transaction Documents exceed
such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by law and applicable to the Transaction Documents
is increased or decreased by statute or any official governmental action subsequent to the date hereof, the new maximum contract rate
of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents from the effective date forward, unless such
application is precluded by applicable law. If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by
the Company or any Purchaser to any Purchaser with respect to indebtedness evidenced by the Transaction Documents, such excess shall
be applied by the Purchaser to the unpaid principal balance of any such indebtedness or be refunded to the Company, the manner of handling
such excess to be at the Purchaser’s election.

 

    	Page 29 of 32

    	 

    

 

5.18
Liquidated Damages. The Company’s and its Subsidiaries obligations to pay any partial liquidated damages or other amounts
owing under the Transaction Documents is a continuing obligation of the Company and its Subsidiaries and shall not terminate until all
unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant
to which such partial liquidated damages or other amounts are due and payable shall have been canceled.

 

5.19
Independent Nature of Purchaser’s Obligations and Rights. The obligations of the Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by the Purchaser pursuant thereto, shall be deemed to constitute the Purchaser as a partnership,
an association, a joint venture or any other kind of entity, or create a presumption that the Purchaser is in any way acting in concert
or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Purchaser shall be entitled
to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement or out of the
other Transaction Documents, and it shall not be necessary for any Purchaser to be joined as an additional party in any proceeding for
such purpose. Purchaser has been represented by its own separate legal counsel in their review and negotiation of the Transaction Documents.
The Company has elected to provide the Purchaser with the same terms and Transaction Documents for the convenience of the Company and
not because it was required or requested to do so by the Purchasers.

 

5.20
Customer Identification - USA Patriot Act Notice; OFAC and Bank Secrecy Act. Purchaser hereby notifies the Company that pursuant
to the requirements of the Act and such Purchaser’s policies and practices, each Purchaser is required to obtain, verify and record
certain information and documentation that identifies the Company, which information includes the name and addresses of Borrower and
such other information that will allow the Purchaser to identify the Company in accordance with the Act. In addition, the Company shall
(a) ensure that no person who owns a controlling interest in or otherwise controls the Company is or shall be listed on the Specially
Designated Nationals and Blocked Person List or other similar lists maintained by OFAC, the Department of the Treasury or included in
any Executive Orders, (b) not use or permit the use of the proceeds of the Note to violate any of the foreign asset control regulations
of OFAC or any enabling statute or Executive Order relating thereto, and (c) comply, and cause any of its Subsidiaries to comply, with
all applicable Bank Secrecy Act (“BSA”) laws and regulations, as amended.

 

(Signature
Pages Follow)

 

    	Page 30 of 32

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	CURATIVE
    BIOTECHNOLOGY CORPORATION, INC.	 	Address
    for Notice: 
	 	 	 	 
	 	 	 	1825
    NW Corporate Blvd. 
	 	 	 	Suite
    110
	 	 	 	Boca
    Raton, FL 33431
	 	 	 	 
	By:	 /s/
    Richard Garr 	 	Telephone:
	Name:	Richard
    Garr	 	Email:
	Title:	CEO	 	 

 

	With
    a copy to (which shall not constitute notice):	 
	 	 
	Telephone:
    	 
	Email:
    	 

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE
PAGE FOR PURCHASER FOLLOWS]

 

    	Page 31 of 32

    	 

    

 

[PURCHASER
SIGNATURE PAGES TO COMPANY, SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

Name
of Investing Entity: ___ Puritan Partners LLC ____________________________________

Signature
of Authorized Signatory of Investing Entity: ___ /s/ Richard Smithline _____________

Name
of Authorized Signatory: ___ Richard Smithline __________________________________

Title
of Authorized Signatory: ___ Managing Member __________________________________

Email
Address of Authorized Entity:_______________________________________________

 

	Address
    for Notice of Investing Entity:	 
	 	 
	 	 
	Address
    for Delivery of Securities for Investing Entity (if not same as above):	 
	 	 
	 	 
	Subscription
    Amount: $	 1,000,000 
	Principal
    Amount of Notes: $	 1,142,857.14 
	Warrants:	 22,857,143 

 

    	Page 32 of 32

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]